KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $1.2 billion.

  • Vertex Pharmaceuticals' Cash from Operations fell 937.36% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year increase of 54125.33%. This contributed to the annual value of -$492.6 million for FY2024, which is 11392.59% down from last year.
  • Vertex Pharmaceuticals' Cash from Operations amounted to $1.2 billion in Q3 2025, which was down 937.36% from $1.1 billion recorded in Q2 2025.
  • Vertex Pharmaceuticals' 5-year Cash from Operations high stood at $1.4 billion for Q3 2024, and its period low was -$3.8 billion during Q2 2024.
  • Over the past 5 years, Vertex Pharmaceuticals' median Cash from Operations value was $956.2 million (recorded in 2022), while the average stood at $681.7 million.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Cash from Operations soared by 67075.61% in 2022 and then crashed by 43088.86% in 2024.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Cash from Operations stood at $995.0 million in 2021, then grew by 8.38% to $1.1 billion in 2022, then plummeted by 78.25% to $234.6 million in 2023, then skyrocketed by 149.19% to $584.6 million in 2024, then skyrocketed by 112.35% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q3 2025, $1.1 billion for Q2 2025, and $818.9 million during Q1 2025.